5EA Stock Chart & Stats
€19.38
€0.00(0.00%)
Market closed
€19.38
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€11.64 - €23.09
Previous CloseN/A
Volume1.00
Average Volume (3M)31.00
Market Cap
€10.77B
Enterprise Value€15.25B
Total Cash (Recent Filing)€428.00M
Total Debt (Recent Filing)€3.99B
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 05, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding499,449,600
10 Day Avg. Volume67
30 Day Avg. Volume31
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.00Price Target Upside34.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.94
Revenue Forecast (FY)€4.46B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained positive free cash flow despite accounting losses indicates the core business generates real cash to fund operations, launches and debt paydown. Durable cash generation reduces refinancing risk, supports the company’s deleveraging path and finances productivity programs without relying on external capital.
Blockbuster New-product AdoptionRapid clinic penetration, high reorder rates and multi-market uptake signal sticky demand and strong competitive positioning for key innovations. Durable adoption of new branded products supports sustainable top-line growth, pricing power and margin expansion as lifecycle sales scale globally.
Improving Leverage And Capital StructureA sizable equity base and a clear deleveraging roadmap provide balance-sheet flexibility. Management’s targeted leverage reduction and >$1B free cash flow goal through 2028 create a credible medium-term path to lower financial risk and enable strategic reinvestment or M&A when execution is proven.
Bears Say
Uneven ProfitabilityPersistent negative net margins and episodic profitability reduce predictability of returns and weaken long-term ROE. Volatility in earnings complicates capital allocation, may constrain dividends or buybacks, and raises the bar for sustaining improvement through margin or volume gains.
Regulatory & Capacity Risk (Zenrelia)Regulatory delays and additional study requirements can postpone U.S. label expansion and full commercial upside, while 24/7 capacity scaling increases execution and capital risk. These structural hurdles could slow realization of product potential and pressure near-to-medium term cash conversion.
Gross Margin PressureInventory cost flow‑through, inflation and mix effects compress gross margins and limit profit leverage from revenue growth. If margin recovery is delayed, it will slow EBITDA conversion, hinder deleveraging targets and reduce the durability of margin improvements from operational initiatives.
5EA FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was €11.64 and its highest was €23.09 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is €10.77B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Aug 05, 2026 which is in 25 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on May 06, 2026. The company reported €0.35 earnings per share for the quarter, beating the consensus estimate of €0.303 by €0.047.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.23.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 499,449,600 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of €0.35 in its last earnings report, beating expectations of €0.303. Following the earnings report the stock price went up 3.492%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in DE:5EA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€26.00 (34.15% Upside)
€26.00 (34.15% Upside)
Blogger Sentiment
Bullish
DE:5EA Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth €174.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.57%
12-Months-Change
Fundamentals
Return on Equity
-3.64%
Trailing 12-Months
Asset Growth
2.17%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
5EA Company Deck
5EA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a materially positive picture: strong Q1 performance (10% organic growth, $1.371B revenue), major share gains and product momentum (Zenrelia, Credelio Quattro and Adtab), raised full-year guidance, meaningful EBITDA and EPS improvement, and a credible path to deleveraging supported by Elanco Ascend productivity plans and disciplined M&A. Near-term headwinds include a 40-basis-point gross margin decline in Q1, higher operating investments, regulatory work required for Zenrelia's U.S. label expansion, capacity scaling needs, and external timing effects (China/Middle East) and competitive risks that could temper near-term upside. Overall, the positives (outperformance, raised guidance, blockbuster product traction and clear balance-sheet focus) outweigh the manageable operational and timing risks discussed.View all DE:5EA earnings summaries5EA Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€26.00
▲(34.15% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Dr Reddy's Laboratories
―
Viatris
―
Teva Pharmaceutical
―
Zoetis
―
Phibro Animal Health
―
Options Prices
Currently, No data available
---











